Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET
Fulcrum Therapeutics (Nasdaq: FULC) announced that it will release its first quarter 2021 financial results on May 6, 2021, prior to market opening. A conference call and webcast are scheduled for 8:00 a.m. ET to discuss these results and the company's recent developments. Fulcrum is focused on treating genetically defined rare diseases, with its lead product, losmapimod, in Phase 2 clinical trials for facioscapulohumeral dystrophy (FSHD) and FTX-6058 in Phase 1 trials for sickle cell disease and beta-thalassemia.
- Advancing losmapimod to Phase 2 clinical development for FSHD.
- FTX-6058 is in Phase 1 clinical development for sickle cell disease and beta-thalassemia.
- None.
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: 800-527-6973
International Dial-in Number: 470-495-9162
Conference ID: 5767008
Replay Dial-in Number: 855-859-2056
Replay International Dial-in Number: 404-537-3406
Conference ID: 5767008
An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
Please visit www.fulcrumtx.com.
Contact:
Christi Waarich
Director, Investor Relations and
Corporate Communications
617-651-8664
cwaarich@fulcrumtx.com
